Related Experiment Video

Updated: Jul 2, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

4-1BB Antibodies in Oncology Clinical Trials: A Review

Robin Schwartz1, Keerti Vajrala2, Gerald S Falchook1

  • 1Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

Journal of Immunotherapy and Precision Oncology
|March 28, 2025
PubMed

Insights

4-1BB agonists are promising cancer immunotherapies that activate T cells. This review covers 4-1BB antibodies in clinical trials, noting their antitumor effects and common side effects.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • 4-1BB (CD137) is a transmembrane glycoprotein on T lymphocytes.
  • 4-1BB signaling promotes T cell activation and differentiation, particularly CD8+ cytotoxic T cells.
  • Its role in enhancing anti-tumor immunity makes it a key target for cancer immunotherapy.

Purpose of the Study:

  • To review the development and clinical application of 4-1BB antibodies in cancer treatment.
  • To summarize the efficacy and safety profiles of 4-1BB targeting agents in ongoing clinical trials.

Main Methods:

  • Literature review of preclinical studies and clinical trials involving 4-1BB antibodies.
  • Analysis of data on therapeutic efficacy and observed adverse events.

Main Results:

  • 4-1BB antibodies demonstrate significant antitumor activity in various preclinical models and human trials.
  • Key observed side effects include transaminase elevation, cytopenias, fatigue, and nausea.
  • Several 4-1BB antibodies are progressing through different phases of clinical oncology trials.

Conclusions:

  • 4-1BB antibodies represent a promising class of immunotherapeutics for cancer treatment.
  • Continued clinical investigation is essential to optimize their use and manage side effects.
  • The therapeutic potential of 4-1BB agonism in oncology is substantial.
Keywords:
4-1BBCD137clinical trialimmunotherapy

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...